Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2020-06-17 Audit Report / Informat…
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Record Date
Audit Report / Information Classification · 85% confidence The document contains audited financial results for the year ended March 31, 2020, prepared under Indian Accounting Standards and as per SEBI Listing Regulations. It also includes auditor's reports, declaration of interim dividend, reappointment of directors, notice of the 37th Annual General Meeting, and board approvals for investments. The presence of audited financial results and auditor's reports for a full fiscal year indicates this is an Annual Report or a filing closely related to it. However, the document length is only 2626 characters, which is quite short for a full Annual Report (10-K). The document includes multiple disclosures and declarations typical of a regulatory filing but not the full detailed annual report itself. Given the inclusion of auditor's reports and financial results, it is more than just an announcement or a regulatory filing. The document is best classified as an Audit Report / Information (AR) because it includes audited financial results and auditor's reports but is not the full Annual Report (10-K).
2020-06-17 English
Fixed Record date as 29th June, 2020 for payment of 4th Interim Dividend
Regulatory Filings
2020-06-17 English
Press Release
Earnings Release Classification · 85% confidence The document contains a brief table of revenue figures segmented by business units for Q4 FY20 and the full fiscal year 2020. The text is very short (416 characters) and only includes financial summary data without detailed analysis, narrative, or comprehensive financial statements. There is no indication that this is a full annual or interim report, nor is it an announcement or presentation. Given the brevity and nature of the content, it best fits the category of an Earnings Release (ER), which typically provides key financial highlights for a quarter or fiscal year without the full detail of a report.
2020-06-17 English
NATCO records INR 2,022.4 Crore consolidated revenue and INR 458.1 Crore of profit, after tax, for the full year ended March 2020
Regulatory Filings
2020-06-17 English
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 17, 2020, inter alia, has considered and approved the following:- Declaration ....
Regulatory Filings
2020-06-17 English
Financial Result Updates
Regulatory Filings
2020-06-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.